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Volume xAvailable online XXXBackground: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the
combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth
factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm
PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab
combined with investigator-selected taxane in this setting.
Patients and methods: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/
mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until
disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included
progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups
according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses
identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse
PFS and OS in subgroups with all, some or none of these factors.
Results: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The
most common grade 3 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the
final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months
overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall.
OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-
negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest
median PFS (13.1 months) and OS (46.3 months).
Conclusions: Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA
and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone
chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design.
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In human epidermal growth factor receptor 2 (HER2)-posi-
tive metastatic breast cancer, results from the randomised
phase III CLinical Evaluation Of Pertuzumab And TRAstuzu-
mab (CLEOPATRA) trial evaluating the addition of pertuzu-
mab to first-line trastuzumab and docetaxel set a new
standard.1-3 Both progression-free survival (PFS) and overall
survival (OS) were significantly improved with dual HER2
blockade compared with a single HER2-directed therapy.
Subsequently, several trials have evaluated alternative reg-
imens, including non-taxane-based chemotherapy agents,
such as vinorelbine and eribulin,4-6 or exchanging intrave-
nous trastuzumab for the subcutaneous formulation.7
PERtUzumab global SafEty (PERUSE), an international
single-arm study, assessed the safety and efficacy of three
widely used taxanes in combination with dual HER2 tar-
geting as first-line therapy for locally recurrent/metastatic
breast cancer (LR/mBC). Preliminary results suggested that
the subgroup of patients receiving paclitaxel with pertuzu-
mab and trastuzumab derived similar efficacy but
experienced fewer toxicities than those treated with a
docetaxel-based regimen.8 Here we report final safety and
efficacy results from the PERUSE study, including pre-
specified subgroup analyses according to hormone receptor
(HR) status and investigator-selected taxane.PATIENTS AND METHODS
The global, open-label, single-arm phase IIIb PERUSE study
(NCT01572038) was designed to evaluate the safety and
tolerability of pertuzumab in combination with trastuzumab
and a taxane. Eligibility criteria have been described in
detail previously.8 In brief, eligible patients had unresect-
able HER2-positive LR/mBC, at least one measurable lesion
and/or non-measurable disease evaluable according to
Response Evaluation Criteria in Solid Tumours (RECIST;
version 1.1), Eastern Cooperative Oncology Group (ECOG)
performance status 2, left ventricular ejection fraction
(LVEF) 50% and no prior systemic therapy (except 2 lines
of endocrine therapy, one of which could have been in
combination with everolimus) for LR/mBC. Prior anti-HER2
therapy (approved or investigational) other than
(neo)adjuvant trastuzumab and/or lapatinib was prohibited.
Patients with disease progression during (neo)adjuvant
trastuzumab and/or lapatinib therapy were excluded, as
were patients with recurrence within 6 months of
completing (neo)adjuvant non-hormonal systemic therapy.
Patients with central nervous system metastases were
eligible if they were stable for 3 months preceding
screening after receiving local therapy without anti-HER2
therapy.
Choice of taxane agent (docetaxel, paclitaxel or nab-
paclitaxel) was at the investigators’ discretion. Taxanes
were administered weekly or every 3 weeks (q3w) in accor-
dance with recognised guidelines and/or local prescribing
information, and given in combination with q3w pertuzumab
(Perjeta®, F. Hoffmann-La Roche Ltd, Basel, Switzerland) at a
dose of 840 mg in cycle 1 followed by 420 mg in subsequent2 https://doi.org/10.1016/j.annonc.2021.06.024cycles, and q3w trastuzumab (Herceptin®, F. Hoffmann-La
Roche Ltd) at a dose of 8 mg/kg in cycle 1 followed
by 6 mg/kg for subsequent cycles. During treatment, patients
were permitted to switch to an alternative taxane per pro-
tocol. Study treatment was administered until unacceptable
toxicity, disease progression, withdrawal of consent or
death, whichever occurred first. Approved endocrine main-
tenance therapies were permitted after discontinuation of
chemotherapy.
Adverse events (AEs) were coded according to Medical
Dictionary for Regulatory Activities (version 21.0) and
severity was graded according to National Cancer Institute
Common Terminology Criteria for Adverse Events (version
4.0). LVEF assessment has been described previously.8
The primary objective of PERUSE was to evaluate the
safety and tolerability of pertuzumab in combination with
trastuzumab and a taxane. Secondary endpoints included
PFS, OS, overall response rate (ORR), clinical benefit rate
(defined as a best response of partial or complete response,
or disease stabilisation maintained for 6 months), dura-
tion of response, time to response and patient-reported
outcomes, assessed using the Functional Assessment of
Cancer TherapydBreast (FACT-B) questionnaire.
Investigators assessed tumour response using computed
tomography or magnetic resonance imaging scans (and
isotope bone scan if indicated) according to RECIST (version
1.1). Objective responses were confirmed 4 weeks after
initial documentation. Tumour assessments were carried out
every three cycles for the first 3 years, and every six cycles
thereafter in patients who remained progression free.
Safety analyses were based on the safety population,
comprising all enrolled patients who received at least one
dose of study treatment. PFS and OS were estimated using
the KaplaneMeier method in the intention-to-treat (ITT)
population, defined as all enrolled patients, and medians
were estimated with 95% confidence intervals (CIs). PFS was
defined as the interval between enrolment and first radio-
graphically documented disease progression according to
RECIST (excluding progression recorded only as ‘clinical pro-
gression’) or death, whichever occurred first. Patients with no
post-baseline tumour assessments were censored on day 1;
those who were alive and progression free or lost to follow-
up were censored at the date of last evaluable tumour
assessment. Patients with two or more missed RECIST scan
visits (19 weeks) were censored at the last evaluable visit
before the missed visits. ORR analysis was based on the best
(confirmed) overall response as assessed by investigators in
all enrolled patients with measurable disease at baseline.
All analyses were descriptive. No formal statistical hy-
pothesis testing was carried out. Prespecified subgroup
analyses of efficacy included subgroups defined by HR sta-
tus, selected taxane, age (<65 versus 65 years), ECOG
performance status (0/1 versus 2), visceral disease at
baseline, prior (neo)adjuvant chemotherapy and prior
trastuzumab. For subgroup analyses by taxane, patients
were analysed according to the first taxane they received
during study therapy. There were no adjustments for mul-
tiplicity of endpoints or comparisons within subgroups. PostVolume xxx - Issue xxx - 2021
D. Miles et al. Annals of Oncologyhoc exploratory multivariable Cox regression analyses
explored the impact of key clinical factors on PFS. Factors
demonstrating prognostic value were used to identify sub-
groups with all, some or none of the risk factors and explore
PFS and OS outcomes between subgroups.
The study was carried out in accordance with the Good
Clinical Practice guidelines and the Declaration of Helsinki,
and all patients provided written informed consent. The
protocol and all accompanying materials provided to pa-




Between 11 May 2012 and 16 September 2014, 1436 pa-
tients were enrolled from sites in Europe, Asia, North and
South America, Africa and Australia and began treatment
with pertuzumab. One patient discontinued therapy
immediately after the first pertuzumab administration and
therefore received neither trastuzumab nor taxane, and
seven additional patients discontinued all study treatments
before receiving their first taxane dose. The initial taxane
selected by the investigator was docetaxel in 775 patients
(54%), paclitaxel in 588 patients (41%) and nab-paclitaxel in
65 patients (5%). Baseline characteristics and prior therapy
(overall and in key subgroups) are summarised in Table 1.Treatment exposure
At the final data cut-off (26 August 2019), the median
duration of follow-up was 68.7 months (95% CI 67.
5-69.3 months; range 0.0-87.3 months), corresponding to











Median (range) 54 (23-87) 53 (23-82) 56 (26-87) 53
>65, n (%) 269 (19) 120 (15) 134 (23) 12
ECOG PS,c n (%)
0 or 1 1371 (95) 754 (97) 547 (93) 64
2 63 (4) 20 (3) 40 (7) 1
Sex, n (%)
Female 1429 (100) 772 (100) 586 (100) 63
Male 7 (<1) 3 (<1) 2 (<1) 2
Race, n (%)
White 1032 (72) 577 (74) 398 (68) 51
Asian 88 (6) 48 (6) 34 (6) 5
Native American 28 (2) 3 (<1) 24 (4) 0
Black 9 (1) 4 (1) 5 (1) 0
Other 57 (4) 37 (5) 18 (3) 2
Not collected per local
regulations
222 (15) 106 (14) 109 (19) 7
Visceral disease, n (%) 992 (69) 547 (71) 397 (68) 42
ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hormone receptor
a Eight patients discontinued all study treatment before receiving taxane.
b Unknown in 6 patients.
c Missing in 2 patients.
Volume xxx - Issue xxx - 202124 cycles (range 1-126 cycles) (corresponding to 16.1
months). The median duration of taxane exposure was 6
cycles (range 1-94 cycles), corresponding to 4.2 months
(Supplementary Table S1, available at https://doi.org/10.
1016/j.annonc.2021.06.024). Median treatment exposure
was longer in patients aged 65 than>65 years (17.5 versus
11.1 months, respectively) and longer in patients who were
trastuzumab naïve than trastuzumab pretreated (17.9 versus
13.2 months, respectively). All but one patient had dis-
continued study treatment by the final analysis. The majority
of patients (62%) discontinued pertuzumab and trastuzumab
because of disease progression (Supplementary Table S2,
available at https://doi.org/10.1016/j.annonc.2021.06.024).
In contrast, taxane therapy was often discontinued for rea-
sons other than progression: in 35% of patients, the primary
reason for stopping taxane was ‘completed regimen’ and a
further 30% stopped at the investigator’s decision. A total
of 295 patients (21%) received maintenance endocrine
therapy, most commonly with an aromatase inhibitor (13%)
or antiestrogen (6%).
Safety
The most common AEs were gastrointestinal and skin/sub-
cutaneous events (Figure 1 and Supplementary Table S3,
available at https://doi.org/10.1016/j.annonc.2021.06.024).
Grade 3 AEs occurred in 61% of patients and were
considered related to pertuzumab in 20% of patients, to
trastuzumab in 17% and to taxane in 36%. The most common
grade 3 AEs were neutropenia (10%) and diarrhoea (8%).
Consistent with the preliminary safety report,8 docetaxel was
associated with higher incidences of grade 3 neutropenia
(15% compared with 5% and 2% in patients treated with












(31-81) 54 (26-83) 55 (23-87) 53 (27-82) 55 (23-87)
(18) 174 (19) 95 (19) 59 (15) 210 (20)
(98) 873 (95) 492 (96) 382 (96) 989 (95)
(2) 44 (5) 19 (4) 18 (5) 45 (4)
(97) 911 (99) 512 (100) 397 (99) 1032 (100)
(3) 7 (1) 0 3 (1) 4 (<1)
(78) 673 (73) 355 (69) 289 (72) 743 (72)
(8) 52 (6) 34 (7) 14 (4) 74 (7)
11 (1) 17 (3) 6 (2) 22 (2)
7 (1) 2 (<1) 2 (1) 7 (1)
(3) 32 (3) 25 (5) 12 (3) 45 (4)
(11) 143 (16) 79 (15) 77 (19) 145 (14)
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Figure 1. Most common adverse events (any grade in ‡20% of patients, grade ‡3 in ‡2%).
Annals of Oncology D. Miles et al.febrile neutropenia (11% compared with 1% and 0% with
paclitaxel and nab-paclitaxel, respectively). Grade 3 diar-
rhoea occurred at a similar incidence with the three taxanes
(8%, 9% and 8%, respectively). Fatal AEs were reported in
31 patients (2%). The only fatal AEs reported in more than
one patient were pneumonia (n ¼ 4), sepsis (n ¼ 3) and
cardiac arrest (n ¼ 2).
AEs led to discontinuation of pertuzumab in 10% of pa-
tients, trastuzumab in 9% of patients and taxane in 20% of
patients. The AEs most commonly leading to treatment
discontinuation were ejection fraction decreased (3%) and
cardiac failure (0.7%) leading to discontinuation of pertu-
zumab and trastuzumab, and peripheral neuropathy (4%),
peripheral sensory neuropathy (2%), paraesthesia (2%),
diarrhoea (1%), fatigue (1%), asthenia (0.9%) and onychol-
ysis (0.6%) leading to taxane discontinuation.
Focusing on AEs of special interest (those previously
associated with pertuzumab), 1 patient (0.1%) had fatal
hepatic failure and 90 patients (6%) experienced an LVEF
decline, comprising ejection fraction decreased in 75
patients (5%), left ventricular dysfunction in 8 patients
(0.6%), cardiac failure in 7 patients (0.5%) and congestive
cardiac failure in 1 patient (0.1%).Efficacy
A confirmed response was recorded in 952 of the 1198
patients with measurable disease, giving an ORR of 79%
(95% CI 77-82%). The clinical benefit rate was 86% (95%4 https://doi.org/10.1016/j.annonc.2021.06.024CI 84-88%). In the 952 responding patients, the median
time to response was 2.5 months (95% CI 2.4-2.5 months)
and the median duration of response was 20.0 months
(95% CI 18.2-22.2 months).
By the final data cut-off, 872 of 1436 patients (61%) had
experienced disease progression or death. This number is
lower than that reported at the interim analysis8 because of a
change before the final analysis to use stricter criteria for
defining disease progression to align with the CLEOPATRA
trial. Median PFS was 20.7 months (95% CI 18.9-23.1 months)
in the ITT population (Figure 2A). Subgroup analyses showed
similar PFS irrespective of HR status (Figure 2B) or taxane
backbone (Figure 2C) but favoured the subgroup with no
prior trastuzumab (Figure 2D).
At the data cut-off, deaths had been recorded in 658
patients (46%), of which 581 (88% of 658) were from pro-
gressive disease. Median OS was 65.3 months (95% CI 60.9-
70.9 months) in the ITT population (Figure 3A). OS was
similar in the subgroups defined by taxane backbone and
the KaplaneMeier curves for docetaxel and paclitaxel were
overlapping (Figure 3C). However, OS was more favourable
in patients with HR-positive disease than HR-negative dis-
ease (Figure 3B), and in those with no prior trastuzumab
than prior trastuzumab (Figure 3D). Efficacy in additional
subgroups is summarised in Table 2.
In post hoc multivariable Cox regression analyses, visceral
disease and prior therapy (trastuzumab or other) were
associated with worse PFS [hazard ratio 1.47 (95%
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Figure 2. PFS: (A) overall, (B) by HR status, (C) by initially selected taxane, (D) by prior trastuzumab.
HR, hormone receptor; PFS, progression-free survival.
D. Miles et al. Annals of Oncology1.29-2.07) for prior trastuzumab; hazard ratio 1.41 (95%
CI 1.10-1.80) for prior therapy other than trastuzumab]
(Table 3). Further exploratory analyses defining subgroupsVolume xxx - Issue xxx - 2021with both, one or neither of these risk factors revealed
considerably worse PFS [median 13.1 months (95% CI 10.6-
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Figure 3. OS: (A) overall, (B) by HR status, (C) by initially selected taxane, (D) by prior trastuzumab.
HR, hormone receptor; OS, overall survival.
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Table 2. Summary of efficacy by subgroup
Subgroup PFS OS
Events, n (%) Median (95% CI), months Events, n (%) Median (95% CI), months
All patients (n ¼ 1436) 872 (61) 20.7 (18.9-23.1) 658 (46) 65.3 (60.9-70.9)
HR positive (n ¼ 918)a 550 (60) 20.6 (18.5-23.8) 411 (45) 66.7 (62.4-77.3)
HR negative (n ¼ 512)a 318 (62) 20.7 (17.1-23.8) 245 (48) 60.2 (52.3-67.7)
Docetaxel (n ¼ 775) 479 (62) 19.4 (16.9-22.1) 351 (45) 66.5 (61.7-77.3)
Paclitaxel (n ¼ 588) 356 (61) 23.2 (19.6-25.6) 273 (46) 64.0 (56.6-72.2)
Nab-paclitaxel (n ¼ 65) 35 (54) 19.2 (11.7-37.1) 28 (43) 70.9 (39.7-NE)
Visceral disease (n ¼ 992) 644 (65) 18.2 (16.1-20.6) 486 (49) 57.1 (52.4-63.4)
Non-visceral disease (n ¼ 444) 228 (51) 27.2 (23.8-34.4) 172 (39) 81.1 (71.7-NE)
Age 65 years (n ¼ 1167) 715 (61) 22.0 (19.6-24.2) 509 (44) 70.0 (64.3-81.1)
Age >65 years (n ¼ 269) 157 (58) 14.7 (12.2-19.5) 149 (55) 50.1 (41.3-54.0)
Prior trastuzumab (n ¼ 400) 274 (69) 15.4 (13.7-19.0) 219 (55) 54.1 (48.7-60.7)
No prior trastuzumab (n ¼ 1036) 598 (58) 23.4 (20.7-25.0) 439 (42) 73.5 (65.6-NE)
CI, confidence interval; HR, hormone receptor; NE, not estimable; OS, overall survival; PFS, progression-free survival.
a HR status unknown in 6 patients.
D. Miles et al. Annals of Oncology262 patients with both visceral disease and prior trastuzu-
mab therapy (Figure 4).Subsequent therapy
By the final data cut-off, post-study anticancer therapy had
been reported in 679 patients (47%). The most commonly
administered anti-HER2 agents were trastuzumab (25%),
trastuzumab emtansine (19%), lapatinib (16%) and pertu-
zumab (7%). The most commonly administered chemo-
therapy agents were capecitabine (20%), vinorelbine (10%)
and taxane (6%). The most commonly administered endo-
crine therapies were aromatase inhibitors (8%) and
antiestrogens (6%).Patient-reported outcomes
At baseline, at least one subscale of the FACT-B question-
naires was completed by 1335 (93%) of 1429 female pa-
tients. Mean (standard deviation) baseline scores at




Age (>65 versus 65 years) 1.18 (0.98-1.43) 0.08
Child-bearing potential (yes versus no) 0.95 (0.81-1.11) 0.51
Visceral disease at baseline (yes versus no) 1.47 (1.26-1.72) <0.0001
Prior therapy 0.0003
Trastuzumab versus none 1.64 (1.29-2.07)
Other versus none 1.41 (1.10-1.80)
Stage at diagnosis 0.30
II versus I 1.18 (0.89-1.56)
III versus I 1.30 (0.98-1.72)
IV versus I 1.28 (0.92-1.79)
Time since primary diagnosis (years) 0.98 (0.95-1.00) 0.08
HR status 0.73
Positive versus negative 0.94 (0.82-1.09)
Unknown versus negative 0.92 (0.34-2.47)
Disease status at diagnosis (locally recurrent
versus metastatic)
1.05 (0.78-1.42) 0.75
Time since diagnosis of metastatic disease
(months)
1.01 (1.00-1.02) 0.15
CI, confidence interval; HR, hormone receptor; PFS, progression-free survival.
a Chi-squared test for the effect.
Volume xxx - Issue xxx - 2021for physical well-being, 22.2 (5.0) for social well-being, 15.1
(5.0) for emotional well-being, 16.7 (6.1) for functional well-
being and 25.0 (6.3) for breast cancer subscale score. As
shown in Supplementary Figure S1, available at https://doi.
org/10.1016/j.annonc.2021.06.024, there was almost no
change from baseline across all timepoints with >10% of
patients completing questionnaires for total FACT-B score or
any of the subscales, and mean changes did not exceed
meaningful thresholds.DISCUSSION
The final analysis of PERUSE represents a mature dataset
(median follow-up approaching 6 years) in a large global pop-
ulation of patients representative of routine oncology practice
in a wide range of health care settings. The patient population
was generally similar to that enrolled in the randomised phase
III CLEOPATRA trial, except for a smaller proportion of patients
with visceral disease (69% versus 88% in CLEOPATRA) and a
larger proportion previously treated with trastuzumab (28%
versus 12% in CLEOPATRA).1 The safety profile of first-line
pertuzumab combined with trastuzumab and standard tax-
ane therapy for HER2-positive LR/mBC in PERUSE was consis-
tent with the known safety profile of the individual agents and
the results from the phase III CLEOPATRA trial.1,2 Safety results
in the final analysis of PERUSE were consistent with the pre-
liminary report, in which AEs were reported according to tax-
ane partner.8 No cumulative toxicities emerged with longer
follow-up and no new safety signals were identified with
alternative taxane backbones.
The final efficacy results provide reassuring evidence of
the effectiveness of pertuzumab, trastuzumab and
investigator-selected taxane. While recognising the limita-
tions of cross-trial comparisons, clinical outcomes with all
three regimens are in line with those reported from
CLEOPATRA (median PFS of 19.2-23.2 months with the
three taxane regimens in PERUSE versus 18.7 months with
pertuzumab, trastuzumab and docetaxel in CLEOPATRA;1
median OS of 64.0-70.9 months in PERUSE versus
57.1 months in CLEOPATRA after >8 years of follow-up at
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Figure 4. Clinical outcomes according to risk factors identified in multivariable analysis: (A) PFS and (B) OS.
CI, confidence interval; PFS, progression-free survival; OS, overall survival.
Annals of Oncology D. Miles et al.favourably with recently published PFS results from the
PUFFIN randomised trial evaluating the CLEOPATRA
regimen in Chinese patients (median PFS of 14.5 months,
OS results immature).9 Comparison with the first rando-
mised trial of trastuzumab in HER2-positive LR/mBC10
highlights the remarkable improvements in the treatment
of this disease since the introduction of HER2-targeted
therapy, notwithstanding the obvious caveats of
comparing trials with different designs in different pop-
ulations and separated temporally by two decades. For8 https://doi.org/10.1016/j.annonc.2021.06.024example, a higher proportion of patients included in the
trial reported by Slamon et al.10 than in PERUSE had
received endocrine therapy in the adjuvant or metastatic
setting before receiving anti-HER2 study therapy with
paclitaxel [48/89 (55%)10 versus 181/589 (31%)8 patients in
H0648g versus PERUSE, respectively].
In PERUSE, patients with HR-positive disease appeared to
have similar PFS but longer OS than those with HR-negative
disease, as would be expected given the natural history of
disease. Unlike CLEOPATRA, patients in PERUSE couldVolume xxx - Issue xxx - 2021
D. Miles et al. Annals of Oncologyreceive maintenance endocrine therapy, which is relatively
widespread in routine practice.11,12 The maintenance
endocrine therapy approach is also similar in some respects
to the chemotherapy cohort of the randomised PERtuzu-
mab and Trastuzumab plus Aromatase INhibitor (PERTAIN)
trial, showing a median PFS of 16.9 months, although in
PERTAIN, taxane therapy was continued for a maximum of
24 weeks before switching to an aromatase inhibitor in
combination with pertuzumab plus trastuzumab.13
Subgroup analyses according to prior trastuzumab
exposure showed a median PFS of 15.4 months in patients
previously treated with trastuzumab, and a median OS of
54.1 months (consistent with a median OS of 53.8 months
in 47 trastuzumab-pretreated patients in CLEOPATRA2,3).
Median PFS and OS were longer in trastuzumab-naïve pa-
tients, but the lack of prior chemotherapy in a substantial
proportion of this subgroup hints at a population enriched
with de novo metastatic disease, associated with a better
prognosis.11 Reports in the literature from registry-based
studies provide differing conclusions on the impact of
prior trastuzumab on outcomes with first-line pertuzumab
plus trastuzumab regimens;14-16 these studies are limited by
their retrospective nature and relatively small sample sizes.
In an analysis of individual patient data from the CLEOPA-
TRA trial, number of metastatic sites and lactate dehydro-
genase level were identified as pretreatment prognostic
markers, but not prior trastuzumab.17 However, in PERUSE,
post hoc multivariable analyses suggested that the presence
of both visceral disease and prior trastuzumab identified a
population with notably worse PFS and OS outcome (me-
dian PFS 13.1 months, median OS 46.3 months) compared
with patients with only one or neither of these risk factors
(median PFS 29.7 months, median OS not reached in pa-
tients with no visceral disease and no prior trastuzumab).
This finding should be taken into consideration when
selecting stratification factors for future trials, and may help
to identify a population in which investigational therapies
may be of particular interest.
Final results from PERUSE complement the pivotal
CLEOPATRA phase III trial results, demonstrating the gen-
eralisability of the findings to a routine clinical practice
setting and the broader applicability of the results to
alternative taxane backbones, particularly paclitaxel. They
also provide important insight into long-term outcomes in
patients with HR-positive disease who may have switched
from taxane chemotherapy to endocrine maintenance
therapy in combination with pertuzumab and trastuzumab.
Median OS exceeding 5.5 years in these patients is note-
worthy. Although the study was not designed specifically to
evaluate this strategy, the large sample size, prospective
nature of the study, rigorous data collection and robust
tumour assessment suggest that this is a reasonable
approach for patients with HR-positive disease. Likewise,
findings in the subgroup of patients treated with paclitaxel,
including a median OS of 64 months (5.3 years), lend sup-
port to the use of this more tolerable chemotherapy part-
ner in combination with first-line pertuzumab andVolume xxx - Issue xxx - 2021trastuzumab in patients for whom docetaxel may not be
considered optimal or appropriate.
In conclusion, final results from the PERUSE study after a
median follow-up of almost 6 years support the use of a
first-line combination of pertuzumab, trastuzumab and
taxane therapy for HER2-positive LR/mBC, and suggest that
paclitaxel is a valid alternative to docetaxel as backbone
chemotherapy. These results add to the existing body of
evidence and reinforce the role of dual HER2 blockade with
pertuzumab and trastuzumab in combination with a taxane
as the standard-of-care first-line regimen for HER2-positive
LR/mBC. Exploratory analyses suggest risk factors that
could guide future trial design.
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